Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2018-08-22 Regulatory Filings
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2018
Regulatory Filings Classification · 100% confidence The document is an announcement by ALK regarding the submission of a registration application for a new drug (tree pollen SLIT-tablet) to European health authorities. It details the regulatory process timeline, clinical trial data (Phase III results), and market implications. This is not a standard periodic financial report (like 10-K or IR), nor is it a management discussion (MDA) or earnings release (ER). It concerns a significant corporate development related to product pipeline and regulatory progress. Since it is a specific announcement about regulatory progress and clinical data that doesn't fit the defined categories like M&A (TAR) or Capital (CAP), it falls best under the general 'Regulatory Filings' (RNS) category as a significant, non-financial regulatory update, or potentially a Legal/Regulatory update (LTR), but RNS is broader for general regulatory news. Given the focus on regulatory submission acceptance, RNS is the most appropriate general regulatory announcement code.
2018-08-22 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a press release from ALK announcing that they have submitted a registration application for their tablet vaccine against tree pollen allergy in Europe. It details the regulatory process, clinical trial data (Phase III), and the expected impact on their product portfolio. Crucially, the document ends with a section titled "Vedhæftet fil" (Attached file) and a link to a file, and it explicitly states, "Disse oplysninger er oplysninger, som ALK-Abelló A/S er forpligtet til at offentliggøre i henhold til EU's markedsmisbrugsforordning." This structure—a brief announcement about a regulatory/business event with an attached file—strongly suggests it is a general regulatory announcement rather than a comprehensive report (like 10-K or IR) or a specific financial release (like ER). Since it is a regulatory announcement that doesn't fit perfectly into other specific categories (like DIRS, DIV, CAP), the most appropriate fallback is Regulatory Filings (RNS). The document length (4127 chars) also supports the idea that this is an announcement of information rather than the full report itself.
2018-08-22 Danish
ALK submits registration application for tree SLIT-tablet in Europe
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse) from ALK-Abelló regarding the submission of a regulatory application for a new tablet vaccine. It details the clinical trial results and the regulatory process. Since it is a general corporate announcement regarding business operations and regulatory milestones that does not fit into specific categories like earnings releases or financial reports, it falls under the 'Regulatory Filings' (RNS) category.
2018-08-22 Danish
ALK submits registration application for tree SLIT-tablet in Europe
Regulatory Filings Classification · 95% confidence The document is a company release (No 11/2018) announcing that ALK has submitted a registration application for a new medical product (tree SLIT-tablet) to European health authorities. It details the clinical trial results supporting the application and the regulatory process. Since this is a general corporate announcement regarding regulatory progress and does not fit into specific categories like financial reports, M&A, or dividends, it falls under the 'Regulatory Filings' (RNS) category as a standard corporate disclosure.
2018-08-22 English
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is a 'Six-month interim report (Q2) 2018' for ALK-Abelló A/S. It contains comprehensive financial statements (Income Statement, Balance Sheet, Cash Flow), detailed management discussion and analysis of business priorities, and financial highlights. It is not a mere announcement (RPA) or a short release, but a full interim financial report. Therefore, it is classified as an Interim / Quarterly Report (IR). H1 2018
2018-08-15 English
Six-month interim report (Q2) 2018
Report Publication Announcement Classification · 95% confidence The document is titled 'Six-month interim report (Q2) 2018' and provides a summary of financial performance, revenue, EBITDA, and strategic progress. While it contains financial data, it is relatively short (4674 characters) and concludes with an 'Attachment' link to the full report, indicating this is a summary announcement of the interim report rather than the full, comprehensive financial filing itself. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement. H1 2018
2018-08-15 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.